Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Colorectal cancer (CRC) organoids can be derived from almost all CRC patients and therefore capture the genetic diversity of this disease. We assembled a panel of CRC organoids carrying either wild-type or mutant RAS, as well as normal organoids and tumor organoids with a CRISPR-introduced oncogenic...

Full description

Bibliographic Details
Main Authors: Carla S Verissimo, René M Overmeer, Bas Ponsioen, Jarno Drost, Sander Mertens, Ingrid Verlaan-Klink, Bastiaan van Gerwen, Marieke van der Ven, Marc van de Wetering, David A Egan, René Bernards, Hans Clevers, Johannes L Bos, Hugo J Snippert
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2016-11-01
Series:eLife
Subjects:
organoids
colorectal cancer
targeted therapy
KRAS
Online Access:https://elifesciences.org/articles/18489

Internet

https://elifesciences.org/articles/18489

Similar Items